Skip to Main Content
Try STAT+ TODAY
Trending:
STAT+
Health
Biotech
First Opinion
The Readout

Biotech’s frothy (and frightful) boom & instant insider trading charges

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Jan. 29, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for January 29, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Study finds supplements of amino acid taurine slow aging…
Study finds supplements of amino acid taurine slow aging in mice and monkeys
The Canada wildfires are exposing the harmful effects —…
The Canada wildfires are exposing the harmful effects — and health inequities — of air pollution
After missing vaccine glory in pandemic, GSK looks to…
After missing vaccine glory in pandemic, GSK looks to dominate other diseases
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories